The company’s proprietary ALLOSTAR platform identified NTS231 by focusing on the KEAP1–NRF2 regulatory axis. By covalently binding to the Cys151 residue of KEAP1, the molecule stabilizes the protein structure to assemble a functional E3-ligase complex, which subsequently degrades NRF2. This mechanism aims to suppress cancer cell viability in tumors that have historically proven difficult to treat due to genetic mutations in NFE2L2, KEAP1, or CUL3.

Preclinical data indicates that NTS231 matches the efficacy of existing clinical-stage compounds while offering improved pharmacokinetic profiles. Testing across patient-derived xenograft models revealed dose-dependent antitumor activity in lung, esophageal, and head and neck cancers. Furthermore, the drug showed potential for combination therapies, particularly when paired with chemotherapy or antibody-drug conjugates to overcome treatment resistance. With IND approval achieved within 24 months of target nomination, Nutshell Therapeutics plans to address an estimated 1.5 million annual cancer cases worldwide driven by NRF2 pathway hyperactivation, a population currently lacking effective targeted options.